FDA
-
-
-
-
-
-
-
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
OPKO Health and Entera Bio expand partnership for oral PTH tablet
-
-
-
-
-
-
-
Entera Bio reports preclinical data for once-daily hypoparathyroidism tablet
-
-
-
-
-
-
-
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
-
-
-
-
-
-
-
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
-
-
-
-
-
-
-
Entera Bio to Participate in Upcoming Events
-
322,256 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

